Artemis Medicare Services Ltd (AMSL) was incorporated in 2004, operates a 541-bedded multi-specialty tertiary care hospital in Gurgaon.
The company possesses a narrow moat based on its quaternary care clinical capabilities and a strong brand in the medical tourism segment, which contributes over 30% of revenue. This is corroborated by an ARPOB that is significantly higher than regional peers, though overall ROCE remains modest due to recent heavy capital expenditure on new towers.
Management is aggressively reinvesting for growth, transitioning from a single-location flagship to a multi-city network including Raipur and South Delhi. While this has temporarily suppressed returns on capital, the focus on asset-light models for new projects (lease/trust land) shows a disciplined approach to avoiding excessive debt.
The aggressive expansion into new geographies and asset-light models failed to replicate the flagship's high-margin clinical success, leading to a permanent drag on returns. The massive 700 crore fundraise and IFC equity conversion diluted existing shareholders into oblivion before the new capacity could reach break-even. Simultaneously, geopolitical shifts choked the medical tourism pipeline, which previously accounted for nearly a third of revenue, leaving the company with high fixed employee costs and un-operationalized towers that never achieved the necessary occupancy to cover the cost of capital.
RichFakir rates Artemis Medicare Services Ltd's business quality as decent — 59/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Artemis Medicare Services Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Artemis Medicare Services Ltd is: Watch — wait for price. A decent business, but at an expensive price against our estimate of fair value — one to keep on the watchlist for a better entry.
RichFakir's educational estimate of Artemis Medicare Services Ltd's fair value is about ₹89 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →